Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients - Charles‐Schoeman, Christina; Fleischmann, Roy; Mysler, Eduardo; Greenwald, Maria; Ytterberg, Steven R.; Koch, Gary G.; Bhatt, Deepak L.; Wang, Cunshan; Mikuls, Ted R.; Chen, All‐shine; Connell, Carol A.; Woolcott, John C.; et al. (Arthritis & rheumatology (Hoboken, N.J.), 2024)
Keywords: Aged; Antirheumatic Agents - adverse effects; Antirheumatic Agents - therapeutic use; Arthritis; Arthritis, Rheumatoid - complications; Arthritis, Rheumatoid - drug therapy; Autoimmune diseases; Body mass index; Body size; Cardiovascular diseases; Embolism; Female; Health risks; Humans; Incidence; Inhibitors; Intervals; Lung diseases; Male; Middle Aged; Piperidines - adverse effects; Piperidines - therapeutic use; Population studies; Proportional Hazards Models; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - therapeutic use; Pulmonary Embolism - epidemiology; Pyrimidines - adverse effects; Pyrimidines - therapeutic use; Pyrroles - adverse effects; Pyrroles - therapeutic use; Regression analysis; Regression models; Rheumatoid arthritis; Risk assessment; Risk Factors; Surveillance; Thromboembolism; Thrombosis; Tumor necrosis factor; Tumor Necrosis Factor Inhibitors - adverse effects; Tumor Necrosis Factor Inhibitors - therapeutic use; Tumor necrosis factor-TNF; Venous Thromboembolism - epidemiology; Venous Thrombosis - chemically induced; Venous Thrombosis - epidemiology